Pioglitazone, which is used to manage T2DM, enhanced the survival of a mouse SOD1 model of ALS; however, a phase II clinical trial suggested that this drug increased the risk of death in ALS patients, although this increase lacked statistical significance [48, 77]). Here, SOD1 is linked to amyotrophic lateral sclerosis.